Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns positive

Q1 FY2026 net change in cash was $9.21M, compared with -$9.46M a year earlier. Trailing-twelve-month net change in cash was -$100M. Over 3 fiscal years it compounded at +42.0% a year.

Context

  • Net change in cash amounted to 201001.7% of revenue in FY2025, up 172169.7 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near $9.21M or moves back toward the trailing-twelve-month quarterly average of -$25M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.21M+182.6% QoQ
Last fiscal yearDec 2025
-$118.59M-193.3% YoY
LTMMar 2026
-$100M-769.9% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+197.4%——
1 year-193.3%——
3-year CAGR+42.0%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(118.59M) USD
Year-over-year change
-193.3%

Net Change in Cash vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -769.9% is the lowest of 9, against a peer median of -69.8%.
  • Net change in cash amounts to 169491.5% of revenue for AVTX, versus a peer median of 23.8%.
AVTX Competitors
Net Change in Cash for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMUXImmunic, Inc.LTM Mar 2026$172.33M USD+307.6%——
ANABAnaptysBio, Inc.LTM Mar 2026$149.83M USD+233.4%—64.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$100M USD-769.9%+42.0%169491.5%
IFRXInflaRx N.V.LTM Mar 2026€22.84M EUR-203.0%-73.8%77884.9%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$17.83M USD+366.8%—19.7%
QTTBQ32 Bio Inc.LTM Mar 2026$14.73M USD-70.6%—27.4%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$2.34M USD-182.5%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.7M USD-69.1%—20.3%
XNCRXencor, Inc.LTM Jun 2026$126K USD-99.1%—0.1%
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding AVTX) —-69.8%-73.8%23.8%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Depreciation & Amortization1.66M166K158K169K344K
Deferred Income Tax22K28K14K114K165K
Stock-Based Compensation8.17M7.55M3.48M5.85M13.62M
Change in Working Capital2.84M(60K)(9.24M)(4.71M)3.84M
Accounts Receivables1.12M2.88M1.78M(475K)0
Inventory(35K)18K20K00
Accounts Payables796K(487K)(2.44M)(163K)(146K)
Other Working Capital961K(2.47M)(8.61M)(4.07M)3.99M
Other Non-Cash Items794K7.22M6.46M(15.35M)8.83M
Operating Cash Flow(70.89M)(26.75M)(30.68M)(49.06M)(51.46M)
Capital Expenditures(113K)(95K)(158K)00
Acquisitions (Net)000356K0
Purchases of Investments0000(113.72M)
Sales of Investments000031.31M
Other Investing Activities0025K0690K
Investing Cash Flow(113K)(95K)(133K)356K(81.72M)
Debt Repayment32.9M(14.81M)(21.24M)00
Common Stock Issued71.93M107K46.22M115.63M15.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.93M067K60.22M(510K)
Financing Cash Flow106.76M(14.7M)25.04M175.85M14.59M
Effect of Forex Changes096K000
Net Change in Cash35.76M(41.45M)(5.77M)127.15M(118.59M)
Free Cash Flow(71.01M)(26.85M)(30.84M)(49.06M)(51.46M)

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.